Among the drugs that will be discussed in Amsterdam over the next three days are bevacizumab, cetuximab, dasatinib, erlotinib, lapatinib, nilotinib, oblimersen sodium, sorafenib, and sunitinib. All of these have been approved or are awaiting regulatory approval in various cancer indications. In addition, a range of agents in earlier phases of development will be discussed. The TAT 2007 program incorporates presentations of results from early-phase clinical trials (phase I and phase II) that have not been released before.
Targeted anticancer agents are the subject of extensive research and development activities worldwide, often conducted in joint projects of academic research institutes and pharmaceutical companies. These drugs are characterized by the fact that they have a well-defined molecular target, which is known to play a role in the growth of tumors or the blood vessels supplying the tumor with nutrients.
Many leading cancer institutes from all over the world are represented at the TAT 2007 conference in Amsterdam. In total, about 600 delegates from over 40 countries will gather at the VU University Main Building in a conference organized by the Amsterdam-based NDDO Research Foundation in a partnership with the European Society for Medical Oncology (ESMO). Professor Giuseppe Giaccone, VU medical center, Amsterdam, is the President of this Conference.